Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
The impact of urinary symptoms in Parkinson disease (PD) extends beyond worsened well-being.
Urinary symptoms common in PD, especially incontinence and nocturia, are major risk factors
for falls likely due to the combination of urinary urgency and impaired mobility (and falls
are a leading cause of mortality in PD), for spouse/caregiver stress due to decreased
mutuality in the relationship, and for institutionalization, largely due to increased
disability. Additionally, most medications currently recommended for urinary symptoms in PD
are anticholinergic and have the potential to worsen the progressive cognitive and autonomic
burdens of the disease. Veterans with PD are also more likely to rely solely on VA for their
health care than Veterans without PD. Thus, optimizing the care of urinary symptoms for
Veterans with PD becomes imperative, particularly for VA. Using a non-inferiority design,
this proposal seeks to demonstrate the comparative effectiveness of pelvic floor muscle
exercise-based behavioral therapy versus drug therapy to treat urinary symptoms in PD.